Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
Provided By PR Newswire
Last update: Aug 6, 2024
– Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million; Positive Momentum ex-US with Continued Regulatory and Reimbursement Approvals –
Read more at prnewswire.com
